All About Bypassing Agents for Hemophilia

Learn more about these treatments for inhibitors.

One of the most problematic issues that can occur with hemophilia are inhibitors—a complication that happens when the body’s immune system targets the factor replacement products meant to help the blood clot properly. When this occurs, the clotting factor becomes inactivated and can’t do its job to stop bleeding. And it happens relatively frequently: Roughly 20% to 30% of people with severe hemophilia A, 5% to 8% of people with mild or moderate hemophilia A, and 4% of people with hemophilia B develop inhibitors. Read more.

Source: National Bleeding Disorders Foundation (NBDF) (formerly National Hemophilia Foundation), HemAware, September 2023.